Arena Pharmaceuticals (ARNA) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Arena Pharmaceuticals (ARNA)

ARNA 99.99

0.0%

Mar 15 5:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

Recommended by:

wolfgangrene

From: PLegee	1/9/2014 4:28:46 PM
	1 Recommendation of 2274

I had the ARNA roll out wrong, I really thought it would hit the market in a big way after the painfully long DEA review (ridiculous bureaucratic incompetence). Sold at higher prices after I was tired of seeing my profit drip away; bought some back at $5. My sense now with the drug effectively demonstrating its efficacy, a Direct to Consumer ad campaign, and Eisai increasing it sales force by over 200 people in the US market, 2014 will see a double in share price during the course of this year. This drug is still on course to be a major player in the obesity market despite whomever else enters the field. And in our back pocket, we still have the Belviq/Phen combo trials. Future looking very good.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next